These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21380938)

  • 1. Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis.
    Farmer JA; Liao J
    Curr Atheroscler Rep; 2011 Apr; 13(2):107-14. PubMed ID: 21380938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-density lipoprotein and atherosclerosis: the role of antioxidant activity.
    Bandeali S; Farmer J
    Curr Atheroscler Rep; 2012 Apr; 14(2):101-7. PubMed ID: 22441969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfunctional high-density lipoprotein and atherosclerosis.
    Ragbir S; Farmer JA
    Curr Atheroscler Rep; 2010 Sep; 12(5):343-8. PubMed ID: 20506005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atheroprotective effects of HDL: beyond reverse cholesterol transport.
    Feig JE; Shamir R; Fisher EA
    Curr Drug Targets; 2008 Mar; 9(3):196-203. PubMed ID: 18336237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis.
    Nofer JR; Brodde MF; Kehrel BE
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):726-35. PubMed ID: 20337657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipoproteins, inflammation and oxidative stress.
    Tabet F; Rye KA
    Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoprotein: a major risk factor for coronary atherosclerosis.
    Miller NE
    Baillieres Clin Endocrinol Metab; 1987 Aug; 1(3):603-22. PubMed ID: 3132134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL-A molecule with a multi-faceted role in coronary artery disease.
    Arora S; Patra SK; Saini R
    Clin Chim Acta; 2016 Jan; 452():66-81. PubMed ID: 26519003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease.
    Kratzer A; Giral H; Landmesser U
    Cardiovasc Res; 2014 Aug; 103(3):350-61. PubMed ID: 24935432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis.
    Miller NE
    Am Heart J; 1987 Feb; 113(2 Pt 2):589-97. PubMed ID: 3544775
    [No Abstract]   [Full Text] [Related]  

  • 11. Atheroprotective effects of high-density lipoproteins.
    Assmann G; Nofer JR
    Annu Rev Med; 2003; 54():321-41. PubMed ID: 12414916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease.
    Brewer HB
    J Clin Endocrinol Metab; 2011 May; 96(5):1246-57. PubMed ID: 21389140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiatherogenic role of high-density lipoprotein cholesterol.
    Kwiterovich PO
    Am J Cardiol; 1998 Nov; 82(9A):13Q-21Q. PubMed ID: 9819099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P).
    Potì F; Simoni M; Nofer JR
    Cardiovasc Res; 2014 Aug; 103(3):395-404. PubMed ID: 24891400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis.
    Meurs I; Van Eck M; Van Berkel TJ
    Curr Pharm Des; 2010 May; 16(13):1445-67. PubMed ID: 20199377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein cholesterol: a potential therapeutic target for prevention of coronary artery disease.
    Chernobelsky A; Ashen MD; Blumenthal RS; Coplan NL
    Prev Cardiol; 2007; 10(1):26-30. PubMed ID: 17215630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL and atherothrombotic vascular disease.
    Annema W; von Eckardstein A; Kovanen PT
    Handb Exp Pharmacol; 2015; 224():369-403. PubMed ID: 25522995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention.
    Ossoli A; Pavanello C; Giorgio E; Calabresi L; Gomaraschi M
    Curr Med Chem; 2019; 26(9):1610-1630. PubMed ID: 29546829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
    Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C
    J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDL and atherosclerosis: Insights from inherited HDL disorders.
    Calabresi L; Gomaraschi M; Simonelli S; Bernini F; Franceschini G
    Biochim Biophys Acta; 2015 Jan; 1851(1):13-8. PubMed ID: 25068410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.